1. Current medical treatment for NAFLD/NASH
- Author
-
Masrour, O, Bardou-Jacquet, Edouard, CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and None
- Subjects
NAFLD ,[SDV]Life Sciences [q-bio] ,NASH ,MAFLD ,Therapy - Abstract
International audience; Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. The high prevalence of NAFLD is related to rising rates of obesity and metabolic syndrome. NAFLD prognosis is most closely linked with fibrosis stage, which can be assessed using non-invasive tests. Therapeutic endpoints include NASH resolution and fibrosis improvement. This hepatic endpoint must be integrated into the overall metabolic issue. Therapeutic strategy is based on lifestyle interventions and weight loss. Indeed, weight loss of 7–10% can reverse liver fibrosis, but adherence to lifestyle changes remains a major problem in real life. There are currently no approved pharmacological treatments for NASH. However, several therapeutic agents are rapidly progressing through the different phases of clinical trials. We provide a summary of recent therapeutic options with most advanced results. © 2023 Société francophone nutrition clinique et métabolisme (SFNCM)
- Published
- 2023
- Full Text
- View/download PDF